The Avibactam spectrum of activity is one of the main reasons this beta-lactamase inhibitor has become an important advancement in modern antimicrobial therapy. As multidrug-resistant bacterial infections continue to increase, clinicians need treatment options that can restore the effectiveness of existing antibiotics. Avibactam plays a key role by protecting certain beta-lactam antibiotics from bacterial enzymes that cause antibiotic resistance.
Although avibactam does not kill bacteria on its own, it expands the activity of companion antibiotics, making them effective against many resistant gram-negative pathogens.
Related: Read our guide on What Is Avibactam?
What Is Avibactam?
Avibactam is a non-beta-lactam beta-lactamase inhibitor. Unlike antibiotics, it does not directly destroy bacteria. Instead, it blocks beta-lactamase enzymes that would otherwise inactivate beta-lactam antibiotics.
It is most commonly used with ceftazidime, forming the combination known as Ceftazidime-Avibactam.
Related: Learn how Avibactam Mechanism of Action works.
What Does the Avibactam Spectrum of Activity Include?
The Avibactam spectrum of activity mainly covers resistant gram-negative bacteria that produce susceptible beta-lactamase enzymes.
It helps restore antibiotic activity against organisms such as:
- Escherichia coli (E. coli)
- Klebsiella pneumoniae
- Enterobacter cloacae
- Citrobacter freundii
- Proteus mirabilis
- Serratia marcescens
- Pseudomonas aeruginosa (many susceptible strains)
These bacteria commonly cause serious hospital-acquired and healthcare-associated infections.
Which Resistance Enzymes Does Avibactam Inhibit?
One reason the Avibactam spectrum of activity is broader than older beta-lactamase inhibitors is its ability to inhibit several important enzyme classes.
Avibactam is active against many:
- Class A beta-lactamases (including KPC enzymes)
- Class C (AmpC) beta-lactamases
- Selected Class D enzymes, including some OXA enzymes
By blocking these enzymes, avibactam protects companion antibiotics from degradation.
What Is Not Covered by Avibactam?
Despite its broad activity, avibactam does not work against every resistance mechanism.
It has limited or no activity against:
- Most metallo-beta-lactamases (MBLs), such as NDM, VIM, and IMP
- Gram-positive bacteria when used alone
- Atypical bacteria
- Viral or fungal infections
Because bacterial resistance varies, culture and susceptibility testing remain essential before treatment.
Clinical Importance
The Avibactam spectrum of activity has expanded treatment options for infections caused by resistant gram-negative bacteria.
Healthcare providers commonly use avibactam-containing therapies for:
- Complicated urinary tract infections (cUTIs)
- Complicated intra-abdominal infections
- Hospital-acquired pneumonia (HAP)
- Ventilator-associated pneumonia (VAP)
- Bloodstream infections caused by susceptible organisms
These infections often occur in hospitalized or critically ill patients.
Why Is the Spectrum of Activity Important?
Knowing which bacteria are covered helps healthcare professionals choose the most appropriate antibiotic therapy.
Understanding the spectrum also supports:
- Appropriate antibiotic selection
- Antimicrobial stewardship
- Reduced unnecessary antibiotic use
- Better patient outcomes
- Slower development of antibiotic resistance
Frequently Asked Questions
Does avibactam kill bacteria directly?
No. Avibactam protects antibiotics from beta-lactamase enzymes but does not directly kill bacteria.
Which bacteria are covered by avibactam?
It helps restore activity against many gram-negative bacteria, including E. coli, Klebsiella pneumoniae, Enterobacter species, and susceptible Pseudomonas aeruginosa.
Does avibactam work against all resistant bacteria?
No. It is ineffective against many metallo-beta-lactamase-producing organisms and some other resistance mechanisms.
Why is susceptibility testing important?
Laboratory testing confirms whether the infecting bacteria are likely to respond to avibactam-containing therapy.
Conclusion
The Avibactam spectrum of activity makes this beta-lactamase inhibitor an important component of modern treatment strategies for resistant gram-negative bacterial infections. By protecting companion antibiotics from several clinically significant beta-lactamase enzymes, avibactam improves the effectiveness of therapy against many difficult-to-treat pathogens.
Healthcare professionals should continue to use avibactam according to culture results, susceptibility testing, and antimicrobial stewardship principles to preserve its long-term effectiveness.